Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
T.MAN Pharmaceutical PCLBKK:TMAN 21 Return-on-Tangible-Equity is 21.55% as of Mar. 2026, which is 31% below its 10-year median of 31.04. GuruFocus rates BKK:TMAN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 901 Drug Manufacturers companies, T.MAN Pharmaceutical PCL ranks better than 84.13% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. T.MAN Pharmaceutical PCL's annualized net income for the quarter that ended in Mar. 2026 was ฿459 Mil. T.MAN Pharmaceutical PCL's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ฿2,127 Mil. Therefore, T.MAN Pharmaceutical PCL's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 21.55%.
The historical rank and industry rank for T.MAN Pharmaceutical PCL's Return-on-Tangible-Equity or its related term are showing as below:
BKK:TMAN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 26.08 Med: 31.04 Max: 45.92
Current: 26.08
During the past 4 years, T.MAN Pharmaceutical PCL's highest Return-on-Tangible-Equity was 45.92%. The lowest was 26.08%. And the median was 31.04%.
BKK:TMAN's Return-on-Tangible-Equity is ranked better than 84.13% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs BKK:TMAN: 26.08
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
T.MAN Pharmaceutical PCL Return-on-Tangible-Equity Related Terms
T.MAN Pharmaceutical PCL Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for T.MAN Pharmaceutical PCL's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:TMAN vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, T.MAN Pharmaceutical PCL's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
T.MAN Pharmaceutical PCL Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, T.MAN Pharmaceutical PCL's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where T.MAN Pharmaceutical PCL's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 21.55% mean?
T.MAN Pharmaceutical PCL (BKK:TMAN) has a Return-on-Tangible-Equity of 21.55% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on T.MAN Pharmaceutical PCL and its competitors. This is 31% below median its historical median of 31.04. Over the past decade, T.MAN Pharmaceutical PCL's Return-on-Tangible-Equity has ranged from 26.08 to 45.92. According to the industry distribution chart, T.MAN Pharmaceutical PCL ranks #143 out of 901 companies in the Drug Manufacturers industry, placing it in the top 15.9%.
Is T.MAN Pharmaceutical PCL's Return-on-Tangible-Equity too high?
T.MAN Pharmaceutical PCL's current Return-on-Tangible-Equity of 21.55% is 31% below median its 10-year median of 31.04. Over the past 10 years, this metric has ranged from a low of 26.08 to a high of 45.92. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. T.MAN Pharmaceutical PCL's value of 21.55% is 173.8% above this industry median. Based on the distribution chart, T.MAN Pharmaceutical PCL ranks #143 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, T.MAN Pharmaceutical PCL has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does T.MAN Pharmaceutical PCL's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, T.MAN Pharmaceutical PCL ranks #143 out of 901 companies for Return-on-Tangible-Equity. This places T.MAN Pharmaceutical PCL in the top 16% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.87. T.MAN Pharmaceutical PCL's value of 21.55% is 173.8% above this benchmark. Historically, T.MAN Pharmaceutical PCL's own Return-on-Tangible-Equity has ranged from 26.08 to 45.92 over the past decade. While the company's 10-year median is 31.04 vs. the industry median of 7.87, T.MAN Pharmaceutical PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. T.MAN Pharmaceutical PCL's current Return-on-Tangible-Equity of 21.55% is 173.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on T.MAN Pharmaceutical PCL and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. T.MAN Pharmaceutical PCL's current Return-on-Tangible-Equity is 21.55%, which is 31% below median its own 10-year median of 31.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T.MAN Pharmaceutical PCL stock overvalued right now?
T.MAN Pharmaceutical PCL (BKK:TMAN) has a current Return-on-Tangible-Equity of 21.55%. The current Return-on-Tangible-Equity is 21.55%, which is 31% below median its 10-year median of 31.04 and 173.8% above the Drug Manufacturers industry median of 7.87. T.MAN Pharmaceutical PCL's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For T.MAN Pharmaceutical PCL (BKK:TMAN), the current Return-on-Tangible-Equity is 21.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
T.MAN Pharmaceutical PCL is engaged in purchasing, importing, manufacturing, and distributing original equipment and in manufacturing, distributing, and exporting modern medicines, traditional medicines, dietary supplements, and healthcare products for the healthcare industry. It offers products through brands such as T.Nutrition, T.Derma, Mommy&Me, TMT, Heaven Herb, and T.Pharmaceutical. The company's reportable segments are: Segment for manufactured products under own brand, which derives key revenue, Segment for manufactured products under third parties' brand, and Segment for trading products.
21GF Score
Get the complete analysis for BKK:TMAN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:TMAN has been successfully added to your 
